Global Anti-Malarial Drugs Market Poised for Strong Growth Potential through 2030: Leading Companies Ipca Laboratories Ltd., Zydus Cadila and More
Malaria is a life-threatening disease caused by parasites that are transmitted to people through the bites of infected mosquitoes. According to the World Health Organization (WHO), there were an estimated 229 million cases of malaria worldwide in 2019, resulting in 409,000 deaths. The majority of deaths occurred in sub-Saharan Africa.
The global anti-malarial drugs market is expected to see significant growth in the coming years. The market is projected to reach $847.1 million by 2030, growing at a CAGR of 4.4% from 2020 to 2030. Key factors driving the growth of the market include increasing initiatives by various government and non-government organizations to eradicate malaria and the development of new drugs for the treatment of malaria.
Leading Companies in the Anti-Malarial Drugs Market
Several key players are operating in the global anti-malarial drugs market, including Ipca Laboratories Ltd., Zydus Cadila, GlaxoSmithKline plc, Novartis AG, Sanofi S.A., and Pfizer Inc. These companies are investing heavily in research and development activities to develop new and effective anti-malarial drugs.
Ipca Laboratories Ltd. is one of the leading companies in the anti-malarial drugs market. The company offers various types of anti-malarial drugs, including artemisinin-based combination therapies (ACTs) and quinoline-based medications. Zydus Cadila is another major player in the market, offering a range of anti-malarial drugs, including artemether-lumefantrine and mefloquine.
The Impact of COVID-19 on the Anti-Malarial Drugs Market
The COVID-19 pandemic has had a significant impact on the global anti-malarial drugs market. According to a report by QY Research, the market size of anti-malarial drugs is expected to decline in 2020 due to the COVID-19 pandemic. However, the market is expected to recover and grow in the coming years, driven by the increasing focus on eradicating malaria.
The Way Forward
The global anti-malarial drugs market is poised for strong growth potential through 2030. While the COVID-19 pandemic has had a temporary impact on the market, the long-term outlook remains positive. Leading companies such as Ipca Laboratories Ltd. and Zydus Cadila are investing in R&D activities to develop new and effective drugs for the treatment of malaria. With increasing initiatives by various government and non-government organizations to eradicate malaria, the demand for anti-malarial drugs is expected to rise in the coming years.
Summary: The global anti-malarial drugs market is expected to grow at a CAGR of 4.4% from 2020 to 2030, reaching $847.1 million by 2030. Leading companies such as Ipca Laboratories Ltd. and Zydus Cadila are investing in R&D activities to develop new and effective drugs for the treatment of malaria. The COVID-19 pandemic has had a temporary impact on the market, but the long-term outlook remains positive. #BUSINESS